Name

PFIZER Manufacturing Belgium

Legal name

Pfizer NV/SA

Website

https://pfizer.be

Company type

Public

Founded year

1952

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ)

akta.pro secondary industries

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB), Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG)

Keywords

• Pharmaceutical manufacturing
• Sterile injectables
• Vaccine production
• Clinical research services
• Pharmaceutical logistics

Headquarters

HQ city

Puurs

HQ country

Belgium

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Pharmaceutical Sales: Sales of prescription medicines across 6 therapeutic areas including oncology, immunology, infectious diseases, and vaccines
2. Vaccine Sales: Production and distribution of vaccines including pneumococcal, meningococcal, COVID-19, and RSV vaccines
3. Not-for-profit access programs: Accord for a Healthier World provides patented medicines and vaccines at not-for-profit prices to 45 lower-income countries

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

PFIZER Manufacturing Belgium operates aseptic manufacturing of sterile injectable medicines and vaccines at its Puurs-Sint-Amands site, producing over 500 million doses annually for patients in 170+ countries. The Belgian operations also include Phase 1 clinical research at the Pfizer Clinical Research Unit (PCRU) in Brussels and a global logistics hub at Zaventem handling two-thirds of Pfizer's worldwide product flows.

Product overview

Pfizer Manufacturing Belgium operates as part of the global Pfizer pharmaceutical network with four complementary Belgian sites: the Global Supply Puurs site (largest European manufacturing and packaging facility), the Pfizer Clinical Research Unit in Brussels (one of only two internal Phase 1 clinical trial centers worldwide), the satellite unit in Hasselt, and the Zaventem Logistics Center (handling two-thirds of Pfizer's global product distribution). The company produces sterile injectable medications and vaccines including pneumococcal, meningococcal, COVID-19, and RSV vaccines, while conducting Phase 1 clinical research and managing global logistics. Major initiatives include the 'An Accord for a Healthier World' program providing medicines at non-profit prices to 45 low-income countries. The Puurs site produces over 400 million units annually for patients in more than 170 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Pfizerpro: Portal for healthcare professionals providing medical information and educational materials

Products and services

• Vaccines A portfolio of vaccines including pneumococcal, meningococcal, tick-borne encephalitis, COVID-19, and RSV vaccines, manufactured under strict quality and safety standards for global distribution.
• Sterile Injectable Medications Sterile injectable medications including oncological treatments, antifungal and anti-infective drugs, pain and anti-inflammatory treatments, immunosuppressants, and injectable contraceptives, serving patients in over 170 countries.
• Phase 1 Clinical Research Services (PCRU) Phase 1 clinical research services conducted at the Pfizer Clinical Research Unit in Brussels and its satellite in Hasselt, conducting early-stage clinical trials testing experimental drugs on humans for cancer, inflammatory diseases, infectious diseases, metabolic diseases, and rare diseases.
• Pneumococcal Conjugate Vaccine Pneumococcal conjugate vaccine (PCV) distributed via Gavi, the Vaccine Alliance, to protect children in low-income countries; more than 1 billion doses delivered to date.
• An Accord for a Healthier World Access program providing patented and off-patent medicines and vaccines at not-for-profit prices to governments of 45 lower-income countries, covering approximately 500 products including chemotherapies, oral cancer treatments, and antibiotics.
• PCRU Satellite Unit Hasselt Satellite Phase 1 clinical research unit at Jessa Hospital in Hasselt, conducting safety studies of new medicines in groups of 10-40 healthy participants as an extension of the Brussels PCRU.

Quantifiable outcome

• 500+ million doses produced annually
• +4 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Ten partnerships are on record, tiered core and flagship.

• ENGIEcoreOthers · 5 October 2023Corporate Power Purchase Agreement (PPA) for renewable energy. Five-year agreement from December 2023 to December 2028. ENGIE manages offshore wind power from C-Power wind park (30 MW allocation to Pfizer). Supports Pfizer's sustainability goal of CO2-neutral operations by 2030 and net zero by 2040.
• UNICEFcoreGTM or Marketing Partner · 5 October 2023Sustainability partnership for vaccine delivery. 30% of Puurs production destined for developing countries through UNICEF distribution networks.
• World Health Organization (WHO)coreGTM or Marketing Partner · 5 October 2023Sustainability partnership for global health programs. 30% of Puurs production destined for developing countries through WHO-supported programs.
• Ghent University (CESPE Innovation Cluster)coreStrategic or Co-development Partner · 4 October 2023Pfizer Puurs officially joined the CESPE innovation cluster, a multi-partner innovation accelerator in pharmaceutical engineering and manufacturing. Collaboration focuses on improving and innovating pharmaceutical manufacturing processes through industry-academia partnership.
• Bill & Melinda Gates FoundationflagshipStrategic or Co-development Partner · 24 May 2022Funding partnership supporting development of Group B Streptococcus (GBS) vaccine candidates for prevention of stillbirth and newborn mortality in lower-income countries. Part of Accord for a Healthier World initiative targeting 1.2 billion people in 45 countries.
• BioNTechflagshipStrategic or Co-development Partner · 5 May 2020Strategic partnership with German biotech company BioNTech to develop mRNA vaccine against COVID-19. Pfizer Puurs played crucial role in manufacturing the vaccine. This partnership resulted in one of the first COVID-19 vaccines to receive emergency use authorization in over 150 countries worldwide.
• Jessa Hospital HasseltcoreStrategic or Co-development Partner · 1 January 2017Clinical research partnership for PCRU satellite unit. Satellite of Pfizer Clinical Research Unit in Brussels opened at Jessa Hospital in 2017 to provide better access to clinical studies for participants in the border region.
• Gavi, the Vaccine AlliancecoreGTM or Marketing Partner · 17 May 2009Pneumococcal Advance Market Commitment (AMC) partnership since 2009. Delivered 1 billionth pneumococcal vaccine dose to Ethiopia. Over 300 million children protected against pneumococcal disease across 57 Gavi-eligible countries. More than 50% of Pfizer's pneumococcal vaccine production supports access in lower-income countries.
• Rwanda (Government)flagshipGTM or Marketing PartnerFirst country to receive Pfizer medicines under Accord for a Healthier World. Rwanda received 9 medicines and vaccines for cancer, infectious and inflammatory diseases. Pfizer provided healthcare professional education and training, and sent Global Health Team to optimize supply chain.
• Ghana, Malawi, Senegal, Uganda (Governments)flagshipGTM or Marketing PartnerAccord for a Healthier World partner countries working with Pfizer on healthcare system strengthening and medicine/vaccine access. First five countries in the initiative covering 45 lower-income countries.

Scale indicators19 records

Recent moves8 records

Expansion highlights6 records

Emerging players

• BioNTech: Pfizer's mRNA co-development partner for the COVID-19 vaccine. Comparable in mRNA technology platform, though BioNTech focuses on R&D and outsources commercial-scale aseptic manufacturing to Puurs and other partners.
• Moderna: Leading mRNA vaccine developer with growing in-house manufacturing capacity. Directly comparable on mRNA platform technology, though smaller and less diversified than Pfizer's Puurs site portfolio of sterile injectables.
• Catalent: Major CDMO providing sterile fill-finish and aseptic manufacturing services to pharma and biotech. Comparable in fill-finish technology and capacity, though operates as a contract manufacturer rather than internal product manufacturer.
• Lonza Group: Leading global CDMO with significant sterile fill-finish and biologics manufacturing capacity. Comparable in aseptic manufacturing capabilities and quality systems, though focused on contract services rather than proprietary product manufacturing.

Broad incumbents

• Roche: Global pharmaceutical incumbent with major biologics and sterile injectable manufacturing, including large-scale European production. Comparable in scale, GMP complexity, and global distribution footprint, though Roche's portfolio skews to biologics/oncology.
• Novartis: Global pharmaceutical incumbent with significant sterile injectable and biologics manufacturing in Europe. Comparable in scale and regulatory complexity; less directly comparable in vaccines.

Direct peers

• Sanofi: Global biopharmaceutical company with major vaccines and sterile injectable manufacturing footprint, including large European production sites. Directly comparable in aseptic vaccine manufacturing, biologics, and global pharmaceutical distribution.
• Merck & Co. (MSD): Global pharmaceutical company with leading vaccine (including pneumococcal via partnership) and sterile injectable portfolios. Comparable in scale, regulatory complexity, and Gavi/governmental immunization program participation.
• GSK (GlaxoSmithKline): Major vaccines and pharmaceuticals manufacturer with a large European manufacturing base. Directly comparable as a top-tier vaccine producer (including pediatric programs) with Gavi partnership and global distribution at scale.
• Johnson & Johnson: Global pharmaceutical manufacturer with vaccines, biologics, and sterile injectable operations across multiple European sites. Comparable in product portfolio breadth, regulatory complexity, and aseptic manufacturing scale.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/pfizerbelgie

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PFIZER Manufacturing Belgium